Cite
MLA Citation
Marc Ferrante et al.. “Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial.” Lancet, vol. 399, no. 10340, 2022, pp. 2031–2046. http://access.bl.uk/ark:/81055/vdc_100155168606.0x00005b